
Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Hematologic Oncology Update
00:00
The Benefits of Getting Off of BTK Inhibitors
Once you kind of get beyond two to three years and you haven't had in toxicity, you typically don't have any issues with the drug. So we do see some immune benefits getting off of these agents. The captivate study has shown some of that data where the B cells come back. T cell activation comes back. And so I think there is absolute benefit to kind of some immune reconstitution as well.
Transcript
Play full episode